Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 19/20 | 0.46 |
| ▸ | PIK3R1 | P27986 | 15/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 11/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 9/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 9/20 | 0.43 |
| ▸ | MTOR | P42345 | 7/20 | 0.43 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.43 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25390708 | 0.87 | HPGD (0.42) | PIK3CDPIK3CBPIK3CG | |
| SCHEMBL27833435 | 0.83 | PIM1 (0.38) | — | |
| SCHEMBL25393024 | 0.82 | PIK3CD (0.44) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL2674162 | 0.78 | PIK3CD (0.47) | PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL30471122 | 0.78 | PIK3CD (0.47) | PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL1113694 | 0.77 | PIK3CD (0.62) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL1192099 | 0.77 | PIK3CA (0.50) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL13828857 | 0.77 | PIK3CA (0.51) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL25391517 | 0.77 | SMN1; SMN2 (0.38) | PIK3CAPIK3R1 | |
| SCHEMBL9936656 | 0.76 | SLC29A1 (0.41) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4694893-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME Therapeutics LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| WO-2024216229-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC (US) | 2024-10-17 | — | — | WO | disclosed |
| EP-4412617-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME Therapeutics LLC (US) | 2024-08-14 | — | — | EP | disclosed |
| US-20230265103-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2023-08-24 | — | — | US | disclosed |
| WO-2023058003-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC (US) | 2023-04-13 | — | — | WO | disclosed |
| EP-2279188-B1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2015-01-28 | — | — | EP | disclosed |
| US-8445487-B2 | Purine PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20120135988-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | CASTANEDO GEORGETTE (US) | 2012-05-31 | — | — | US | disclosed |
| US-8158624-B2 | Purine PI3K inhibitor compounds and methods of use | GENETECH, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| CN-102105474-A | Purine PI3K inhibitor compounds and methods of use | GENENTECH INC | 2011-06-22 | — | — | CN | disclosed |
| EP-2279188-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2011-02-02 | — | — | EP | disclosed |
| US-20090318411-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2009-12-24 | — | — | US | disclosed |
| WO-2009146406-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265103-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | PIKFYVE, PIK3CD, PIK3R5 | PIK3CA 6/4885PIK3R1 25/4885PIK3CD 2/4885 |
| US-20090318411-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CG | PIK3CA 1/4885PIK3R1 17/4885PIK3CD 2/4885 |
| US-20120135988-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CG | PIK3CA 1/4885PIK3R1 17/4885PIK3CD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.